PROPHETMELANOMA

Medical analysis services; medical analysis services for the prediction of response to cancer treatment; medical analysis services for clinical outcomes associated with cancer treatment; medical analysis services for identification of new drug targets for cancer treatment; medical analysis services for the prediction of response to cancer treatment based on computational analysis of patient's proteins; medical analysis services for discovering new targets for overcoming cancer drug resistance, based on computational analysis of patient's proteins; medical analysis services to support decision-making regarding the treatment of cancer patients; medical analysis services to support treatment decisions in cancer patients; medical analysis services for the prediction of patients' response to cancer treatment and the identification of associated biological mechanisms.